Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LINC01410 inhibitor
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
LINC01410 inhibitors are therapeutic agents designed to target and downregulate the long non-coding RNA (lncRNA) LINC01410. LINC01410 is an oncogenic lncRNA that is overexpressed in various malignancies, including multiple myeloma, colon cancer, gastric cancer, and gallbladder cancer, where it promotes tumor cell proliferation, migration, invasion, and cell cycle progression. In multiple myeloma, LINC01410 interacts with the minichromosome maintenance (MCM) complex (specifically subunits MCM4, MCM5, and MCM7) to modulate the DNA replication machinery. Experimental approaches to inhibit LINC01410 include antisense oligonucleotides (ASOs), such as gapmeRs, and small interfering RNAs (siRNAs) to induce RNAseH1-mediated or RNAi-mediated degradation of the transcript.
- Other names
- LINC01410 inhibitorsLINC-01410 inhibitorsLINC 01410 inhibitors
02
Targets
MCM4 (Minichromosome maintenance complex component 4)MCM5 (Minichromosome maintenance complex component 5)MCM7 (DNA replication licensing factor MCM7)
Beyond the preview
Go deeper on LINC01410 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LINC01410 inhibitor.